14063

    524212

    WANBURY

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    WANBURY LIMITED Share Price Today

    WANBURY LIMITED is currently trading at ₹293.55, down by ₹4.1 from the previous close. The stock touched an intraday high of ₹301.55 and a low of ₹292.00 during the latest trading session. Over the past one year, WANBURY LIMITED has delivered a return of 12.38%, while the stock has gained 5.98% in the last one month.

    WANBURY LIMITED performance

    Today’s low Today’s high
    ₹ 292.00 ₹ 301.55
    ₹ 293.55
    52 week low 52 week high
    ₹ 161.50 ₹ 358.85
    ₹ 293.55
    Open Price ₹ 298.95
    Prev. Close ₹ 297.65
    Volume (Shares) 118849.00
    Total traded value ₹ 348.88
    Upper Circuit ₹ 357.15
    Lower Circuit ₹ 238.15
    info

    Investment Returns

    Over 1 Month 5.98% Over 3 Months 17.05% Over 6 Months 42.58% Over 1 Year 12.38%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    WANBURY LIMITED fundamentals


    • Market cap (Cr) 1,025.60
    • P/E Ratio (TTM) 15.76
    • Beta 1.22
    • Book Value / share 41.34
    • Return on equity 18.30%
    • EPS (TTM) 19.95
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 21.70
    info icon alternate text
    • Market cap (Cr) 1,027.40
    • P/E Ratio (TTM) 15.76
    • Beta 1.00
    • Book Value / share 41.34
    • Return on equity 18.30%
    • EPS (TTM) 19.95
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 21.70
    info icon alternate text

    WANBURY LIMITED Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 164.58
    Operating Expense 146.02
    Net Profit 21.70
    Net Profit Margin (%) 13.18
    Earnings Per Share (EPS) 7.26
    EBITDA 26.46
    Effective Tax Rate (%) -43.11
    Particulars DEC 2025 (Values in Cr)
    Revenue 162.45
    Operating Expense 146.76
    Net Profit 15.76
    Net Profit Margin (%) 9.70
    Earnings Per Share (EPS) 4.52
    EBITDA 26.86
    Effective Tax Rate (%) 0.69
    Particulars SEP 2025 (Values in Cr)
    Revenue 160.06
    Operating Expense 145.10
    Net Profit 15.18
    Net Profit Margin (%) 9.48
    Earnings Per Share (EPS) 4.58
    EBITDA 25.98
    Effective Tax Rate (%) -0.13
    Particulars JUN 2025 (Values in Cr)
    Revenue 163.18
    Operating Expense 149.92
    Net Profit 13.49
    Net Profit Margin (%) 8.26
    Earnings Per Share (EPS) 4.12
    EBITDA 24.79
    Effective Tax Rate (%) 0.88
    Particulars MAR 2025 (Values in Cr)
    Revenue 172.00
    Operating Expense 154.79
    Net Profit 20.26
    Net Profit Margin (%) 11.77
    Earnings Per Share (EPS) 6.18
    EBITDA 31.46
    Effective Tax Rate (%) -6.29
    Particulars MAR 2026 (Values in Cr)
    Revenue 650.27
    Operating Expense 587.80
    Net Profit 66.13
    Net Profit Margin (%) 10.16
    Earnings Per Share (EPS) 20.42
    EBITDA 104.09
    Effective Tax Rate (%) -10.58
    Particulars MAR 2025 (Values in Cr)
    Revenue 599.51
    Operating Expense 573.46
    Net Profit 30.53
    Net Profit Margin (%) 5.09
    Earnings Per Share (EPS) 9.32
    EBITDA 79.81
    Effective Tax Rate (%) -3.31
    Particulars MAR 2024 (Values in Cr)
    Revenue 575.65
    Operating Expense 547.85
    Net Profit 30.40
    Net Profit Margin (%) 5.28
    Earnings Per Share (EPS) 9.29
    EBITDA 72.99
    Effective Tax Rate (%) 1.23
    Particulars MAR 2023 (Values in Cr)
    Revenue 499.65
    Operating Expense 510.25
    Net Profit -10.40
    Net Profit Margin (%) -2.08
    Earnings Per Share (EPS) -3.18
    EBITDA 23.48
    Effective Tax Rate (%) -1.06
    Particulars MAR 2022 (Values in Cr)
    Revenue 511.19
    Operating Expense 507.93
    Net Profit 81.47
    Net Profit Margin (%) 15.93
    Earnings Per Share (EPS) 25.29
    EBITDA 113.19
    Effective Tax Rate (%) -0.43
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 16.26
    ROE % 19.98
    ROCE % 21.03
    Total Debt to Total Equity 3.38
    EBITDA Margin 13.90
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 6.70
    ROE % 49.77
    ROCE % 33.46
    Total Debt to Total Equity 0.00
    EBITDA Margin 13.14
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share -10.07
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 5.43
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share -7.27
    ROE % 306.03
    ROCE % 16.14
    Total Debt to Total Equity 0.00
    EBITDA Margin 7.33
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share -62.46
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 5.20
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 16.26
    ROE % 18.30
    ROCE % 19.97
    Total Debt to Total Equity 3.38
    EBITDA Margin 13.31
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 6.70
    ROE % 38.26
    ROCE % 31.94
    Total Debt to Total Equity 8.94
    EBITDA Margin 12.63
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share -2.26
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.70
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 0.57
    ROE % 37.03
    ROCE % 17.45
    Total Debt to Total Equity 0.00
    EBITDA Margin 7.26
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share -52.23
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 5.20
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 12.82
    Total Assets 413.91
    Total Liabilities 413.91
    Total Equity 59.27
    Share Outstanding 3
    Price to Book Ratio 14.43
    Return on Assets (%) 7.37
    Return on Capital (%) 13.13
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 5.89
    Total Assets 343.49
    Total Liabilities 343.49
    Total Equity 27.94
    Share Outstanding 3
    Price to Book Ratio 21.77
    Return on Assets (%) 16.29
    Return on Capital (%) 40.58
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 3.93
    Total Assets 303.52
    Total Liabilities 303.52
    Total Equity -32.81
    Share Outstanding 3
    Price to Book Ratio -16.51
    Return on Assets (%) -3.42
    Return on Capital (%) -33.19
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 25.31
    Total Assets 352.54
    Total Liabilities 352.54
    Total Equity -23.41
    Share Outstanding 3
    Price to Book Ratio 149.12
    Return on Assets (%) 23.10
    Return on Capital (%) 186.85
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 11.70
    Total Assets 289.17
    Total Liabilities 289.17
    Total Equity -156.24
    Share Outstanding 2
    Price to Book Ratio -1.59
    Return on Assets (%) -4.35
    Return on Capital (%) -301.65
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 12.82
    Total Assets 413.91
    Total Liabilities 413.91
    Total Equity 59.27
    Share Outstanding 3
    Price to Book Ratio 14.43
    Return on Assets (%) 7.37
    Return on Capital (%) 13.13
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 5.89
    Total Assets 343.11
    Total Liabilities 343.11
    Total Equity 27.94
    Share Outstanding 3
    Price to Book Ratio 21.77
    Return on Assets (%) 8.85
    Return on Capital (%) 22.15
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 3.89
    Total Assets 301.89
    Total Liabilities 301.89
    Total Equity -7.25
    Share Outstanding 3
    Price to Book Ratio -16.51
    Return on Assets (%) -3.44
    Return on Capital (%) -18.28
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 25.27
    Total Assets 351.00
    Total Liabilities 351.00
    Total Equity 2.18
    Share Outstanding 3
    Price to Book Ratio 149.12
    Return on Assets (%) 23.21
    Return on Capital (%) 117.72
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 11.66
    Total Assets 287.60
    Total Liabilities 287.60
    Total Equity -130.65
    Share Outstanding 2
    Price to Book Ratio -1.59
    Return on Assets (%) -4.38
    Return on Capital (%) -42.35
    Particulars MAR 2025 (Values in Cr)
    Net Income 29.55
    Cash from Operations 26.47
    Cash from Investing -51.17
    Cash from Financing 25.73
    Net change in Cash 0.66
    Free Cash Flow 75.49
    Particulars MAR 2024 (Values in Cr)
    Net Income 56.33
    Cash from Operations 4.16
    Cash from Investing -16.62
    Cash from Financing 14.55
    Net change in Cash 1.90
    Free Cash Flow 21.58
    Particulars MAR 2023 (Values in Cr)
    Net Income -10.28
    Cash from Operations 19.97
    Cash from Investing -8.83
    Cash from Financing -31.99
    Net change in Cash -21.03
    Free Cash Flow 32.59
    Particulars MAR 2022 (Values in Cr)
    Net Income 81.12
    Cash from Operations 40.68
    Cash from Investing 0.58
    Cash from Financing -28.58
    Net change in Cash 12.52
    Free Cash Flow 50.34
    Particulars MAR 2021 (Values in Cr)
    Net Income -12.40
    Cash from Operations 17.81
    Cash from Investing 8.04
    Cash from Financing -17.38
    Net change in Cash 7.34
    Free Cash Flow 22.24
    Particulars MAR 2025 (Values in Cr)
    Net Income 29.55
    Cash from Operations 26.47
    Cash from Investing -51.17
    Cash from Financing 25.73
    Net change in Cash 0.66
    Free Cash Flow 75.49
    Particulars MAR 2024 (Values in Cr)
    Net Income 30.78
    Cash from Operations 4.88
    Cash from Investing -16.62
    Cash from Financing 13.87
    Net change in Cash 1.94
    Free Cash Flow 22.30
    Particulars MAR 2023 (Values in Cr)
    Net Income -10.28
    Cash from Operations 19.97
    Cash from Investing -8.83
    Cash from Financing -31.99
    Net change in Cash -21.03
    Free Cash Flow 32.59
    Particulars MAR 2022 (Values in Cr)
    Net Income 81.12
    Cash from Operations 40.68
    Cash from Investing 0.58
    Cash from Financing -28.58
    Net change in Cash 12.52
    Free Cash Flow 50.34
    Particulars MAR 2021 (Values in Cr)
    Net Income -12.40
    Cash from Operations 17.81
    Cash from Investing 8.04
    Cash from Financing -17.38
    Net change in Cash 7.34
    Free Cash Flow 22.24
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 13.96 1.62 257.79 23.12 38.85
    BLISS GVS PHARMA LTD 454.10 36.50 4.03 4816.01 118.35 552.90
    CIPLA LTD. 1466.00 33.09 3.43 118430.12 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 465.55 21.78 3.36 1370.16 256.40 482.70
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 23.52 4.33 257.79 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 518.30 23.23 4.04 1498.44 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8090.05 105.72 23.17 20225.13 7630.00 9850.00
    BLISS GVS PHARMA LTD 454.10 49.09 4.16 4816.01 118.35 552.90

    WANBURY LIMITED shareholding pattern

    Holding
    56.02%
    43.01%
    0.89%
    0.06%
    86.69%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    WANBURY LIMITED Technicals Summary

    293.55 -1.37 redarrow
    red-green-graph indicator
    11 Bearish
    5 Bullish
    • 5 Days 311.70
    • 26 Days 307.90
    • 10 Days 316.80
    • 50 Days 294.00
    • 12 Days 316.60
    • 100 Days 277.70
    • 20 Days 312.10
    • 200 Days 264.90
    303.78 PIVOT
    First Support 289.57 First Resistance 311.87 Second Support 281.48 Second Resistance 326.08 Third Support 267.27 Third Resistance 334.17
    RSI 44.97 ADX 35.76 MACD 8.69 Williams % R -96.00 Commodity Channel Index (CCI) -33.90
    Date 2026-07-30 Week 123093.00 Same Day 142200.00 Month 209249.00
    1 Year 1.22 3 Year 1.13
    Over 1 Month
    5.98% down
    Over 1 Year
    12.38% down
    Over 3 Months
    17.05% down
    Over 3 Years
    79.57% down
    Over 6 Months
    42.58% down
    Over 5 Years
    28.29% down

    WANBURY LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
    12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
    13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
    20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
    28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
    12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
    13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
    20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
    28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares

    Top Gainers

    Top Losers

    Wanbury share result highlights

    The Wanbury share price has experienced fluctuations following the company’s recent financial results. Wanbury reported moderate revenue growth, driven by strong demand in the pharmaceutical sector. However, profit margins were impacted by rising input costs and operational expenses. The company’s focus on expanding its product portfolio and enhancing its manufacturing capabilities contributed positively to overall revenue. Despite these efforts, net profit remained under pressure, reflecting the challenges faced in maintaining profitability. Nevertheless, Wanbury’s strategic initiatives in research and development have positioned it for future growth, keeping the Wanbury share price stable, with cautious optimism from investors about the company’s long-term performance.

    Wanbury share annual reports

    Wanbury’s annual reports provide a comprehensive overview of the company’s financial performance, which directly impacts the Wanbury share price. The reports highlight key metrics such as revenue growth, operational efficiency, and cost management. They also outline the company’s strategic initiatives, including investments in research and development, which are essential for future growth. Investors use these reports to assess Wanbury’s financial stability and long-term potential. The annual reports are crucial for understanding the company’s progress and the factors that drive the Wanbury share price, offering valuable insights into its operational and financial outlook.

    Wanbury share dividend

    Wanbury has not been a regular dividend-paying company in recent years due to its focus on reinvesting profits into business expansion and research initiatives. The company’s primary goal has been to strengthen its financial position and improve operational efficiencies. As a result, dividend payments have been limited, which may not attract income-focused investors. However, as Wanbury continues to stabilise its financial performance, future dividend payouts may become a possibility. This strategic reinvestment has helped support the long-term stability of the Wanbury share price.

    Popular FAQs

    Who is the CEO of Wanbury?

    As of the latest available information, the CEO of Wanbury is Mr. Arvind Doshi. He is responsible for overseeing the company’s strategic direction and overall operations, which directly impact the Wanbury share price. His focus on expanding Wanbury’s product offerings and strengthening its position in the pharmaceutical sector plays a key role in driving the company’s financial performance and long-term growth.

     

    When was Wanbury established?

    Wanbury was established in 1990. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry, specialising in active pharmaceutical ingredients and formulations. Over the years, Wanbury has expanded its operations, contributing to its strong market presence. This long-standing history has had a positive impact on the Wanbury share price, reflecting the company’s stability and growth potential.

     

    What factors influence the Wanbury share price?

    Several factors influence the Wanbury share price, including the company’s financial performance, revenue growth, and profitability margins. External factors such as regulatory changes, demand for pharmaceutical products, and market competition also play a significant role. Additionally, investor sentiment regarding Wanbury’s ability to manage costs, expand its product portfolio, and maintain profitability affects the share price movement.

     

    Is Wanbury debt free?

    Wanbury is not entirely debt-free, but it maintains a manageable level of debt. The company’s focus on effective debt management ensures that its financial obligations do not negatively impact its profitability. This controlled debt structure contributes to the overall stability of the Wanbury share price, as investors generally prefer companies with a balanced approach to managing liabilities and sustaining long-term growth.

     

    How has the Wanbury share price performed over the past year?

    Over the past year, the Wanbury share price has experienced moderate fluctuations, reflecting the company’s financial performance and market conditions. While the company has seen revenue growth, challenges related to rising input costs and operational expenses have impacted profitability. Despite these hurdles, the Wanbury share price has remained relatively stable, with investors maintaining cautious optimism about the company’s future growth potential.

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Wanbury Ltd?

    Answer Field

    Wanbury Ltd share price is for NSE ₹ 293.55 & for BSE ₹ 293.60 as on Jul 31 2026 03:30 PM.

    What is the Market Cap of Wanbury Ltd Share?

    Answer Field

    The market cap of Wanbury Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 31 2026 03:30 PM.

    What is the 52 Week High and Low of Wanbury Ltd?

    Answer Field

    The 52 Week High and Low of Wanbury Ltd for NSE is ₹ 358.85 and ₹ 161.50 and for BSE is ₹ 360.00 and ₹ 162.00.

    What is 1 year return for Wanbury Ltd?

    Answer Field

    The 1 year returns on the stock has been 12.38%.

    What is the P/E Ratio of Wanbury Ltd Share?

    Answer Field

    As on Jul 31 2026 03:30 PM the price-to-earnings (PE) ratio for Wanbury Ltd share is 15.76.

    What is the PB ratio of Wanbury Ltd Share?

    Answer Field

    As on Jul 31 2026 03:30 PM, the price-to-book (PB) ratio for Wanbury Ltd share is 41.34.

    How to Buy Wanbury Ltd Share?

    Answer Field

    You can trade in Wanbury Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Wanbury Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Wanbury Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Wanbury Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    Who is the CEO of Wanbury?

    Answer Field

    As of the latest available information, the CEO of Wanbury is Mr. Arvind Doshi. He is responsible for overseeing the company’s strategic direction and overall operations, which directly impact the Wanbury share price. His focus on expanding Wanbury’s product offerings and strengthening its position in the pharmaceutical sector plays a key role in driving the company’s financial performance and long-term growth.

    When was Wanbury established?

    Answer Field

    Wanbury was established in 1990. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry, specialising in active pharmaceutical ingredients and formulations. Over the years, Wanbury has expanded its operations, contributing to its strong market presence. This long-standing history has had a positive impact on the Wanbury share price, reflecting the company’s stability and growth potential.

    What factors influence the Wanbury share price?

    Answer Field

    Several factors influence the Wanbury share price, including the company’s financial performance, revenue growth, and profitability margins. External factors such as regulatory changes, demand for pharmaceutical products, and market competition also play a significant role. Additionally, investor sentiment regarding Wanbury’s ability to manage costs, expand its product portfolio, and maintain profitability affects the share price movement.

    Is Wanbury debt free?

    Answer Field

    Wanbury is not entirely debt-free, but it maintains a manageable level of debt. The company’s focus on effective debt management ensures that its financial obligations do not negatively impact its profitability. This controlled debt structure contributes to the overall stability of the Wanbury share price, as investors generally prefer companies with a balanced approach to managing liabilities and sustaining long-term growth.

    How has the Wanbury share price performed over the past year?

    Answer Field

    Over the past year, the Wanbury share price has experienced moderate fluctuations, reflecting the company’s financial performance and market conditions. While the company has seen revenue growth, challenges related to rising input costs and operational expenses have impacted profitability. Despite these hurdles, the Wanbury share price has remained relatively stable, with investors maintaining cautious optimism about the company’s future growth potential.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |